A double-blind placebo-controlled trial of maca root as treatment for antidepressant-induced sexual dysfunction in women

Christina M Dording, Pamela J Schettler, Elizabeth D Dalton, Susannah R Parkin, Rosemary S W Walker, Kara B Fehling, Maurizio Fava, David Mischoulon, Christina M Dording, Pamela J Schettler, Elizabeth D Dalton, Susannah R Parkin, Rosemary S W Walker, Kara B Fehling, Maurizio Fava, David Mischoulon

Abstract

Objective. We sought to demonstrate that maca root may be an effective treatment for antidepressant-induced sexual dysfunction (AISD) in women. Method. We conducted a 12-week, double-blind, placebo-controlled trial of maca root (3.0 g/day) in 45 female outpatients (mean age of 41.5 ± 12.5 years) with SSRI/SNRI-induced sexual dysfunction whose depression remitted. Endpoints were improvement in sexual functioning as per the Arizona Sexual Experience Scale (ASEX) and the Massachusetts General Hospital Sexual Function Questionnaire (MGH-SFQ). Results. 45 of 57 consented females were randomized, and 42 (30 premenopausal and 12 postmenopausal women) were eligible for a modified intent-to-treat analysis based on having had at least one postmedication visit. Remission rates by the end of treatment were higher for the maca than the placebo group, based on attainment of an ASEX total score ≤ 10 (9.5% for maca versus 4.8% for placebo), attaining an MGH-SFQ score ≤ 12 (30.0% for maca versus 20.0% for placebo) and reaching an MGH-SFQ score ≤ 8 (9.5% for maca versus 5.0% for placebo). Higher remission rates for the maca versus placebo group were associated with postmenopausal status. Maca was well tolerated. Conclusion. Maca root may alleviate SSRI-induced sexual dysfunction in postmenopausal women. This trial is registered with NCT00568126.

References

    1. Williams V. S. L., Edin H. M., Hogue S. L., Fehnel S. E., Baldwin D. S. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. Journal of Psychopharmacology. 2010;24(4):489–496. doi: 10.1177/0269881109102779.
    1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th. Washington, DC, USA: American Psychiatric Association; 2000.
    1. Montejo-González A. L., Llorca G., Izquierdo J. A., et al. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. Journal of Sex and Marital Therapy. 1997;23(3):176–194. doi: 10.1080/00926239708403923.
    1. Cassano P., Fava M. Tolerability issues during long-term treatment with antidepressants. Annals of Clinical Psychiatry. 2004;16(1):15–25. doi: 10.1080/10401230490281618.
    1. Moynihan R. FDA panel rejects testosterone patch for women on safety grounds. The British Medical Journal. 2004;329(7479, article 1363) doi: 10.1136/bmj.329.7479.1363.
    1. Safarinejad M. R., Hosseini S. Y., Asgari M. A., Dadkhah F., Taghva A. A randomized, double-blind, placebo-controlled study of the efficacy and safety of bupropion for treating hypoactive sexual desire disorder in ovulating women. BJU International. 2010;106(6):832–839. doi: 10.1111/j.1464-410X.2010.09208.x.
    1. Segraves R. T., Clayton A., Croft H., Wolf A., Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. Journal of Clinical Psychopharmacology. 2004;24(3):339–342. doi: 10.1097/01.jcp.0000125686.20338.c1.
    1. Nurnberg H. G., Hensley P. L., Gelenberg A. J., Fava M., Lauriello J., Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. Journal of the American Medical Association. 2003;289(1):56–64. doi: 10.1001/jama.289.1.56.
    1. Chivers M. L., Rosen R. C. Phosphodiesterase Type 5 inhibitors and female sexual response: faulty protocols or paradigms? The Journal of Sexual Medicine. 2010;7(2):858–872. doi: 10.1111/j.1743-6109.2009.01599.x.
    1. Mischoulon D. Polypharmacy and side effects management with natural psychotropic medications. In: Mischoulon D., Rosenbaum J., editors. Natural Medications for Psychiatric Disorders: Considering the Alternatives. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 2002. pp. 207–215.
    1. Chacon R. C. A study of the chemical composition of Lepidium meyenii [Dissertation] Lima, Peru: Universidad Nacional Mayor de San Marcos; 1961.
    1. Chung F., Rubio J., Gonzales C., Gasco M., Gonzales G. F. Dose-response effects of Lepidium meyenii (Maca) aqueous extract on testicular function and weight of different organs in adult rats. Journal of Ethnopharmacology. 2005;98(1-2):143–147. doi: 10.1016/j.jep.2005.01.028.
    1. Cicero A. F. G., Bandieri E., Arletti R. Lepidium meyenii Walp. Improves sexual behavior in male rats independently from its action on spontaneous locomotor activity. Journal of Ethnopharmacology. 2001;75(2-3):225–229. doi: 10.1016/s0378-8741(01)00195-7.
    1. Cicero A. F. G., Piacente S., Plaza A., Sala E., Arletti R., Pizza C. Hexanic Maca extract improves rat sexual performance more effectively than methanolic and chloroformic Maca extracts. Andrologia. 2002;34(3):177–179. doi: 10.1046/j.1439-0272.2002.00490.x.
    1. Gonzales G. F., Gasco M., Córdova A., Chung A., Rubio J., Villegas L. Effect of Lepidium meyenii (Maca) on spermatogenesis in male rats acutely exposed to high altitude (4340 m) Journal of Endocrinology. 2004;180(1):87–95. doi: 10.1677/joe.0.1800087.
    1. Gonzales G. F., Miranda S., Nieto J., et al. Red Maca (Lepidium meyenii) reduced prostate size in rats. Reproductive Biology and Endocrinology. 2005;3, article 5 doi: 10.1186/1477-7827-3-5.
    1. Zhang Y., Yu L., Ao M., Jin W. Effect of ethanol extract of Lepidium meyenii Walp. on osteoporosis in ovariectomized rat. Journal of Ethnopharmacology. 2006;105(1-2):274–279. doi: 10.1016/j.jep.2005.12.013.
    1. Zheng B. L., He K., Kim C. H., et al. Effect of a lipidic extract from Lepidium meyenii on sexual behavior in mice and rats. Urology. 2000;55(4):598–602. doi: 10.1016/s0090-4295(99)00549-x.
    1. Gonzales G. F., Cordova A., Gonzales C., Chung A., Vega K., Villena A. Lepidium meyenii (Maca) improved semen parameters in adult men. Asian Journal of Andrology. 2001;3(4):301–303.
    1. Brooks N. A., Wilcox G., Walker K. Z., Ashton J. F., Cox M. B., Stojanovska L. Beneficial effects of Lepidium meyenii (Maca) on psychological symptoms and measures of sexual dysfunction in postmenopausal women are not related to estrogen or androgen content. Menopause. 2008;15(6):1157–1162. doi: 10.1097/gme.0b013e3181732953.
    1. Dording C. M., Fisher L., Papakostas G., et al. A double-blind, randomized, pilot dose-finding study of maca root (L. Meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience and Therapeutics. 2008;14(3):182–191. doi: 10.1111/j.1755-5949.2008.00052.x.
    1. Gonzales G. F., Córdova A., Vega K., et al. Effect of Lepidium meyenii (MACA) on sexual desire and its absent relationship with serum testosterone levels in adult healthy men. Andrologia. 2002;34(6):367–372. doi: 10.1046/j.1439-0272.2002.00519.x.
    1. Zenico T., Cicero A. F. G., Valmorri L., Mercuriali M., Bercovich E. Subjective effects of Lepidium meyenii (Maca) extract on well-being and sexual performances in patients with mild erectile dysfunction: a randomized, double-blind clinical trial. Andrologia. 2009;41(2):95–99. doi: 10.1111/j.1439-0272.2008.00892.x.
    1. Meissner H. O., Kapczynski W., Mscisz A., Lutomski J. Use of gelatinized maca (Lepidium peruvianum) in early postmenopausal women—a pilot study. International Journal of Biomedical Science. 2005;1(1):33–45.
    1. Lee M. S., Shin B.-C., Yang E. J., Lim H.-J., Ernst E. Maca (Lepidium meyenii) for treatment of menopausal symptoms: a systematic review. Maturitas. 2011;70(3):227–233. doi: 10.1016/j.maturitas.2011.07.017.
    1. Srikugan L., Sankaralingam A., McGowan B. First case report of testosterone assay-interference in a female taking maca (Lepidium meyenii) BMJ Case Reports. 2011 doi: 10.1136/bcr.01.2011.3781.
    1. Bogani P., Simonini F., Iriti M., et al. Lepidium meyenii (Maca) does not exert direct androgenic activities. Journal of Ethnopharmacology. 2006;104(3):415–417. doi: 10.1016/j.jep.2005.09.028.
    1. Gonzalez G. F., Córdova A., Vega K., Chung A., Villena A., Góñez C. Effect of Lepidium meyenii (Maca), a root with aphrodisiac and fertility-enhancing propeties, on serum reproductive hormone levels in adult healthy men. Journal of Endocrinology. 2003;176(1):163–168. doi: 10.1677/joe.0.1760163.
    1. Hamilton M. Development of a rating scale for primary depressive illness. The British Journal of Social and Clinical Psychology. 1967;6(4):278–296. doi: 10.1111/j.2044-8260.1967.tb00530.x.
    1. Hamilton M. The assessment of anxiety states by rating. The British Journal of Medical Psychology. 1959;32(1):50–55. doi: 10.1111/j.2044-8341.1959.tb00467.x.
    1. Labbate L. A., Lare S. B. Sexual dysfunction in male psychiatric outpatients: validity of the Massachusetts General Hospital sexual functioning questionnaire. Psychotherapy and Psychosomatics. 2001;70(4):221–225. doi: 10.1159/000056257.
    1. Mcgahuey C. A., Gelenberg A. J., Laukes C. A., et al. The arizona sexual experience scale (ASEX): reliability and validity. Journal of Sex and Marital Therapy. 2000;26(1):25–40. doi: 10.1080/009262300278623.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. revised. Rockville, Md, USA: National Institute of Mental Health; 1976.
    1. Kellner R. A symptom questionnaire. The Journal of Clinical Psychiatry. 1987;48(7):268–274.
    1. Demers L. M. Androgen deficiency in women: role of accurate testosterone measurements. Maturitas. 2010;67(1):39–45. doi: 10.1016/j.maturitas.2010.04.019.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren